Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Veracyte Inc - SIC # 8071 - MEDICAL LABORATORIES
Ticker
Exchange
SIC #
Website
Latest Ticker
VCYT
Nasdaq
8071
https://www.veracyte.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Veracyte Inc
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
- Apr 22nd, 2024 9:00 pm
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
- Apr 22nd, 2024 12:30 pm
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
- Apr 16th, 2024 12:30 pm
What Makes Veracyte (VCYT) a Lucrative Investment?
- Apr 2nd, 2024 2:33 pm
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
- Feb 27th, 2024 10:55 pm
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
- Feb 26th, 2024 8:20 pm
Veracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Feb 24th, 2024 1:13 pm
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript
- Feb 23rd, 2024 4:10 pm
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
- Feb 23rd, 2024 12:43 pm
Q4 2023 Veracyte Inc Earnings Call
- Feb 23rd, 2024 12:37 pm
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
- Feb 22nd, 2024 11:05 pm
Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook
- Feb 22nd, 2024 9:40 pm
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
- Feb 22nd, 2024 9:05 pm
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
- Feb 21st, 2024 10:00 pm
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Feb 8th, 2024 1:00 pm
Veracyte Completes Acquisition of C2i Genomics
- Feb 6th, 2024 1:15 pm
3 Medical Instruments Stocks to Buy as Industry Trends Improve
- Jan 23rd, 2024 3:13 pm
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
- Jan 8th, 2024 1:00 pm
The Zacks Analyst Blog Highlights Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath
- Jan 5th, 2024 2:42 pm
5 Top-Ranked Cathie Wood Stocks to Buy Right Now
- Jan 4th, 2024 1:40 pm
Scroll